Management of gynecological cancers in the COVID-19 era: A survey from Turkey

Simple item page
dc.contributor.authorAltın D.
dc.contributor.authorYalçın İ.
dc.contributor.authorKhatib G.
dc.contributor.authorKeleşoğlu M.D.
dc.contributor.authorAkgöl S.
dc.contributor.authorÖnder A.B.
dc.contributor.authorKahramanoğlu İ.
dc.contributor.authorGüvenal T.
dc.contributor.authorTopuz S.
dc.contributor.authorDemirkıran F.
dc.date.accessioned2024-07-22T08:07:46Z
dc.date.available2024-07-22T08:07:46Z
dc.date.issued2020
dc.description.abstractObjective: This study aimed to investigate how gynecologic oncologists modified their patient management during Coronavirus disease-2019 (COVID-19) in Turkey. Material and Methods: An online survey was sent to gynecologic oncology specialists and fellows in Turkey. It included management questions about strategies for newly diagnosed or recurrent endometrial, cervical, ovarian and vulvar cancer during the pandemic. Participants were asked if treatment of these cancers can be delayed or not and, if yes, the duration of delay. Results: 32.9% of surgeons prescribed oral or intrauterine progesterone for early stage, low-grade endometrial cancer. Conversely, 65.7% and 45.7% of the most surgeons did not change their management for early stage high-grade and advanced stage endometrial cancers respectively, as they perform surgery. 58% and 67.1% of the surgeons continued to prefer standard surgical treatment for microinvasive and early stage cervical cancers, respectively. Radiotherapy was preferred administered with hypofractionated doses for locally advanced cervical cancer (57.1%). While 67.1% of surgeons operated early stage ovarian cancer patients, 50% administered neoadjuvant chemotherapy (NACT) to all advanced stage ovarian cancers and 50% administered more cycles of NACT in preference to interval debulking surgery. 93.7% of the surgeons responded that treatment should not be delayed beyond eight weeks. Conclusion: Most Turkish gynecologic oncologists modified their management of gynecologic cancers due to the COVID-19 pandemic. While chemotherapy was preferred for ovarian cancer, postponement of the surgery, with or without non-surgical options, was considered for early stage, low-grade endometrial cancer. Treatment of gynecologic cancers should be decided on a case by case basis, taking into account local COVID-19 infection rates and availability of health facilities. Prognosis is also an important consideration if delay is contemplated. Standard treatment and normal time-frames should be used if possible. If not, a postponement for a maximum of eight weeks or referral to another center were acceptable alternatives. © 2020 by the Turkish-German Gynecological Education and Research Foundation.
dc.identifier.DOI-ID10.4274/jtgga.galenos.2020.2020.0071
dc.identifier.issn13090399
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/14072
dc.language.isoEnglish
dc.publisherGalenos
dc.rightsAll Open Access; Gold Open Access
dc.subjectprogesterone
dc.subjectArticle
dc.subjectcancer grading
dc.subjectcancer radiotherapy
dc.subjectcancer staging
dc.subjectcoronavirus disease 2019
dc.subjectcytoreductive surgery
dc.subjectendometrium cancer
dc.subjectfemale
dc.subjectfemale genital tract cancer
dc.subjecthealth care facility
dc.subjecthuman
dc.subjecthypofractionated radiotherapy
dc.subjectinfection rate
dc.subjectlaparoscopy
dc.subjectlaparotomy
dc.subjectneoadjuvant chemotherapy
dc.subjectonline analysis
dc.subjectovary cancer
dc.subjectpandemic
dc.subjectquestionnaire
dc.subjectuterine cervix cancer
dc.subjectvulvar cancer
dc.titleManagement of gynecological cancers in the COVID-19 era: A survey from Turkey
dc.typeArticle

Files

Collections

Scopus Koleksiyonu